Moberg Pharma
ISIN: SE0013121340 | Ticker: MOB | LEI: 549300XFXK7DVGDRP410
Country: Sweden
s of April 2019, Moberg Pharma focuses on the commercialization of its clinical pipeline with a combined peak sales potential estimated at USD 350–700 million. MOB-015 is a next generation nail fungus treatment, and BUPI is a novel treatment for oral pain relief in association with inflammation and ulceration of the oral mucous membranes (oral mucositis or OM), a serious complication of cancer treatment. Both drugs have demonstrated strong clinical results which indicate that they have the potential to become market leaders in their respective niches.
Moberg Pharma has secured commercialization partners for MOB-015 in Europe, Japan, Canada, Israel and the Republic of Korea. MOB-015 has recently been evaluated over 52 weeks in two randomized, multicenter, controlled Phase 3 studies, including in total more than 800 patients in North America and Europe. The primary endpoint was met in both studies, the proportion of patients achieving complete cure of their target nail.
2006
HeadquartersGustavslundsvägen 42, 16751 Bromma – Sweden
| Line item in (sek) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Assets | N/A | 450,889,000.00 | 564,423,000.00 |
| Noncurrent Assets | N/A | 346,234,000.00 | 436,663,000.00 |
| Office Equipment | N/A | 0.00 | 0.00 |
| Intangible Assets Other Than Goodwill | N/A | 327,042,000.00 | 408,104,000.00 |
| Intangible Assets Under Development | N/A | 327,042,000.00 | 408,104,000.00 |
| Deferred Tax Assets | N/A | 14,673,000.00 | 22,575,000.00 |
| Other Noncurrent Assets | N/A | 19,192,000.00 | 28,559,000.00 |
| Current Assets | N/A | 104,655,000.00 | 127,760,000.00 |
| Current Trade Receivables | N/A | 474,000.00 | 383,000.00 |
| Current Prepayments | N/A | 862,000.00 | 772,000.00 |
| Cash and cash equivalents | 29,285,000.00 | 102,655,000.00 | 125,550,000.00 |
| Equity And Liabilities | N/A | 450,889,000.00 | 564,423,000.00 |
| Equity | 395,577,000.00 | 434,051,000.00 | 533,584,000.00 |
| Issued Capital | N/A | 4,405,000.00 | 9,827,000.00 |
| Retained Earnings | N/A | -301,730,000.00 | -317,440,000.00 |
| Additional Paidin Capital | N/A | 731,376,000.00 | 841,197,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 434,051,000.00 | 533,584,000.00 |
| Liabilities | N/A | 16,838,000.00 | 30,839,000.00 |
| Noncurrent Liabilities | N/A | 1,300,000.00 | 4,053,000.00 |
| Other Noncurrent Liabilities | N/A | 65,000.00 | 65,000.00 |
| Current Liabilities | N/A | 15,538,000.00 | 26,786,000.00 |
| Accruals Classified As Current | N/A | 6,565,000.00 | 6,544,000.00 |
| Other Current Liabilities | N/A | 970,000.00 | 1,017,000.00 |
| Line item in (sek) | 01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|
| Revenue From Contracts With Customers | 0.00 | 207,000.00 |
| Other Income | 2,227,000.00 | 1,815,000.00 |
| Profit Loss From Operating Activities | -19,730,000.00 | -20,226,000.00 |
| Finance Income | 0.00 | 786,000.00 |
| Finance Costs | 240,000.00 | 72,000.00 |
| Profit Loss Before Tax | -19,970,000.00 | -19,512,000.00 |
| Income Tax Expense Continuing Operations | -3,748,000.00 | -3,802,000.00 |
| Profit Loss From Continuing Operations | -16,222,000.00 | -15,710,000.00 |
| Profit Loss From Discontinued Operations | 23,589,000.00 | 0.00 |
| Profit (loss) | 7,367,000.00 | -15,710,000.00 |
| Profit Loss Attributable To Owners Of Parent | 7,492,000.00 | -15,710,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | -125,000.00 | 0.00 |
| Line item in (sek) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Profit (loss) | N/A | 7,367,000.00 | -15,710,000.00 |
| Adjustments For Income Tax Expense | N/A | 0.00 | 0.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 2,584,000.00 | 2,582,000.00 |
| Adjustments For Sharebased Payments | N/A | 631,000.00 | 1,458,000.00 |
| Adjustments For Fair Value Gains Losses | N/A | 0.00 | 0.00 |
| Cash Flows From Used In Operations | N/A | -15,296,000.00 | -16,842,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 240,000.00 | 71,000.00 |
| Interest Received Classified As Operating Activities | N/A | 0.00 | 0.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 9,999,000.00 | 0.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 31,309,000.00 | 68,072,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -41,308,000.00 | -68,072,000.00 |
| Proceeds From Issuing Shares | N/A | 133,438,000.00 | 109,682,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 3,464,000.00 | 1,873,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 129,974,000.00 | 107,809,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 73,370,000.00 | 22,895,000.00 |
| Cash and cash equivalents | 29,285,000.00 | 102,655,000.00 | 125,550,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 11.11.21 | Mark Beveridge | Other | Buy | SEK 17,730.00 |
| 10.11.21 | Mark Beveridge | Other | Buy | SEK 17,310.00 |
| 09.11.21 | Mark Beveridge | Other | Buy | SEK 29,800.00 |
| 10.02.21 | Cindy Wong | Other | Buy | SEK 31,675.00 |
| 09.02.21 | Cindy Wong | Other | Buy | SEK 30,800.00 |
SE0013121340
LEI549300XFXK7DVGDRP410
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.